Vinorelbine tartrate and Hair loss - a phase IV clinical study of FDA data
Summary:
Hair loss is found among people who take Vinorelbine tartrate, especially for people who are female, 50-59 old, have been taking the drug for < 1 month.
The phase IV clinical study analyzes which people take Vinorelbine tartrate and have Hair loss. It is created by eHealthMe based on reports of 2,402 people who have side effects when taking Vinorelbine tartrate from the FDA, and is updated regularly. You can use the study as a second opinion to make health care decisions.
Phase IV trials are used to detect adverse drug outcomes and monitor drug effectiveness in the real world. With medical big data and AI algorithms, eHealthMe is running millions of phase IV trials and makes the results available to the public. Our original studies have been referenced on 600+ medical publications including The Lancet, Mayo Clinic Proceedings, and Nature.
2,402 people reported to have side effects when taking Vinorelbine tartrate.
Among them, 46 people (1.92%) have Hair loss.
What is Vinorelbine tartrate?
Vinorelbine tartrate has active ingredients of vinorelbine tartrate. eHealthMe is studying from 2,409 Vinorelbine tartrate users for its effectiveness, alternative drugs and more.
What is Hair loss?
Hair loss is found to be associated with 3,883 drugs and 3,356 conditions by eHealthMe.
Number of Vinorelbine tartrate and Hair loss reports submitted per year:

Time on Vinorelbine tartrate when people have Hair loss *:
- < 1 month: 52 %
- 1 - 6 months: 48 %
- 6 - 12 months: 0.0 %
- 1 - 2 years: 0.0 %
- 2 - 5 years: 0.0 %
- 5 - 10 years: 0.0 %
- 10+ years: 0.0 %
Gender of people who have Hair loss when taking Vinorelbine tartrate *:
- female: 92.68 %
- male: 7.32 %
Age of people who have Hair loss when taking Vinorelbine tartrate *:
- 0-1: 0.0 %
- 2-9: 0.0 %
- 10-19: 0.0 %
- 20-29: 5 %
- 30-39: 0.0 %
- 40-49: 15 %
- 50-59: 65 %
- 60+: 15 %
Common drugs people take besides Vinorelbine tartrate *:
- Taxotere: 29 people, 63.04%
- Ondansetron: 24 people, 52.17%
- Ventolin: 20 people, 43.48%
- Codeine: 17 people, 36.96%
- Herceptin: 17 people, 36.96%
- Keppra: 16 people, 34.78%
- Navelbine: 15 people, 32.61%
- Senna: 15 people, 32.61%
- Paracetamol: 14 people, 30.43%
- Xeloda: 13 people, 28.26%
Common side effects people have besides Hair loss *:
- Fatigue (feeling of tiredness): 41 people, 89.13%
- Nausea (feeling of having an urge to vomit): 40 people, 86.96%
- Diarrhea: 39 people, 84.78%
- Neuropathy Peripheral (surface nerve damage): 36 people, 78.26%
- Headache (pain in head): 31 people, 67.39%
- Mucosal Inflammation (infection of mucous membrane): 31 people, 67.39%
- Heart Palpitations (feelings or sensations that your heart is pounding or racing): 30 people, 65.22%
- Nasopharyngitis (inflammation of the nasopharynx): 30 people, 65.22%
- Cough: 27 people, 58.70%
- Rashes (redness): 26 people, 56.52%
Common conditions people have *:
- Diarrhea: 30 people, 65.22%
- Breast Cancer: 27 people, 58.70%
- Breast Cancer Metastatic: 26 people, 56.52%
- Epilepsy (common and diverse set of chronic neurological disorders characterized by seizures): 22 people, 47.83%
- Wheezing (a high-pitched whistling sound made while you breath): 22 people, 47.83%
- Headache (pain in head): 19 people, 41.30%
- Constipation: 18 people, 39.13%
- Oropharyngeal Pain: 18 people, 39.13%
- Muscle Twitching: 18 people, 39.13%
- Muscle Spasms (muscle contraction): 18 people, 39.13%
* Approximation only. Some reports may have incomplete information.
Do you take Vinorelbine tartrate and have Hair loss?
Check whether Hair loss is associated with a drug or a conditionHow to use the study?
You can discuss the study with your doctor, to ensure that all drug risks and benefits are fully discussed and understood.
Related publications that referenced our studies
- Lindsey SF, Tosti A, "Hair loss induced by tumor necrosis factor alpha inhibitors", J Clin Investigat Dermatol, 2015 Jan .
Related studies
How severe was Hair loss and when was it recovered:
Expand to all the drugs that have ingredients of vinorelbine tartrate:
Alternative drugs to, pros and cons of Vinorelbine tartrate:
- Vinorelbine tartrate (2,409 reports)
Common Vinorelbine tartrate side effects:
- Agranulocytosis (a deficiency of granulocytes in the blood, causing increased vulnerability to infection): 341 reports
- Fever: 170 reports
- Diarrhea: 152 reports
- Fatigue (feeling of tiredness): 148 reports
- Breathing difficulty: 126 reports
- Pneumonia: 120 reports
Browse all side effects of Vinorelbine tartrate:
a b c d e f g h i j k l m n o p q r s t u v w x y zHair loss treatments and more:
- Hair loss (238,701 reports)
COVID vaccines that are related to Hair loss:
- Hair loss in Moderna COVID Vaccine
- Hair loss in Pfizer BioNTech Covid Vaccine
- Hair loss in Johnson and Johnson Covid Vaccine
Common drugs associated with Hair loss:
- Taxotere: 34,064 reports
- Docetaxel: 25,062 reports
- Methotrexate: 16,710 reports
- Humira: 14,833 reports
- Enbrel: 14,300 reports
- Prednisone: 13,908 reports
- Neosar: 11,976 reports
- Remicade: 10,226 reports
- Orencia: 9,671 reports
- Arava: 8,730 reports
All the drugs that are associated with Hair loss:
- Hair loss (3,883 drugs)
Common conditions associated with Hair loss:
- Rheumatoid arthritis: 18,564 reports
- Multiple sclerosis: 13,366 reports
- Breast cancer: 11,002 reports
- Chemotherapy: 8,910 reports
- High blood pressure: 5,484 reports
All the conditions that are associated with Hair loss:
- Hair loss (3,356 conditions)
How the study uses the data?
The study uses data from the FDA. It is based on vinorelbine tartrate (the active ingredients of Vinorelbine tartrate) and Vinorelbine tartrate (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.
Who is eHealthMe?
With medical big data and proven AI algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 600+ medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).
WARNING, DISCLAIMER, USE FOR PUBLICATION
WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.
DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.
If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.
Recent studies on eHealthMe:
- Prednisone and Odefsey drug interaction - 24 seconds ago
- Augmentin and Gastrointestinal Disorder - 37 seconds ago
- Paracetamol vs. Dolophine Hydrochloride - 42 seconds ago
- Asmanex Twisthaler and Renal Failure Acute - 49 seconds ago
- Provera and Eyelid Infection - 50 seconds ago
- Nuedexta and Ventricular Tachycardia - a minute ago
- Ferrous Fumarate and Hepatic Cirrhosis - a minute ago
- Sulfamethoxazole And Trimethoprim Double Strength and Faeces Discolored - a minute ago
- Aleve and Noctiva drug interaction - a minute ago
- Cuts And Puncture Wounds and Lip Swelling - a minute ago